The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Myeloma XI long-term follow-up: Graham Jackson update
Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK, discusses data from the long-term follow-up of the Myeloma XI trial (NCT01554852). Myeloma XI is a multicenter, randomized controlled trial for newly diagnosed multiple myeloma (MM), with pathways for transplant eligible and non-eligible patients. This trial compared triplet induction regimens containing lenalidomide or thalidomide and maintenance treatment with lenalidomide or observation. Results show the use of lenalidomide, as both induction and maintenance, was associated with the best outcomes irrespective of cytogenetic risk group. Additionally, Prof. Jackson introduces other studies investigating secondary primary malignancies (SPMs). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
